Plasma amyloid precursor protein is decreased in Alzheimer’s disease

R. N. Martins*, J. Muir, W. S. Brooks, H. Creasey, P. Montgomery, P. Sellers, G. A. Broe

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


Alzheimer’s disease is characterized by amyloid deposits whose major protein component is βA4. βA4 is a product of the amyloid precursor protein (APP). APP was assayed in partially purified plasma samples from 16 sporadic Alzheimer’s disease patients, 12 age-matched controls, 15 Down’s syndrome individuals aged 19-36 years and 8 young to middle-aged controls (22-51 years). 14 of the 16 Alzheimer’s disease patients had decreased plasma APP when compared with age-matched controls. 14 of the 15 Down’s syndrome individuals had similar levels of APP when compared with age-matched and elderly non-demented controls by immunoblotting, whereas one had levels of APP less than controls. Taken together with results from a previous report (Lancet 1992; 340:453-454), the decreased plasma APP levels mirror the changes observed with cerebrospinal fluid APP levels in Alzheimer’s disease.

Original languageEnglish
Pages (from-to)757-759
Number of pages3
Issue number6
Publication statusPublished - 1993
Externally publishedYes


  • Alzheimer’s disease
  • Amyloid precursor protein
  • Blood plasma
  • Heparin sepharose
  • Platelets


Dive into the research topics of 'Plasma amyloid precursor protein is decreased in Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this